REVELATION BIOSCIENCES, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
REVELATION BIOSCIENCES, INC. (REVB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.29 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2022-04-15
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-12-31 was $727.40K.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-09-30 was $509.97K.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-06-30 was $700.50K.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-03-31 was $349.86K, a 1501.13% increase year-over-year.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $2.29M, a 6673.88% increase from fiscal 2020.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $33.77K, a 828.34% increase from fiscal 2019.
- REVELATION BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $3.64K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 1 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $727.40K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | $1.24M derived: sum of 2 quarters · filed 2022-04-15 | $1.94M derived: sum of 3 quarters · filed 2022-04-15 | $2.29M 10-K · filed 2022-04-15 | ||
| 2021-09-30 | $509.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $1.21M derived: sum of 2 quarters · filed 2021-10-29 | $1.56M 10-Q · filed 2021-10-29 | |||
| 2021-06-30 | $700.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-23 | $1.05M 10-Q · filed 2021-08-23 | ||||
| 2021-03-31 | $349.86K 10-Q · filed 2021-06-22 | |||||
| 2020-12-31 | $33.77K 10-K · filed 2022-04-15 | $30.13K 10-K · filed 2021-03-31 | ||||
| 2020-03-31 | $21.85K 10-Q · filed 2021-06-22 | |||||
| 2019-12-31 | $3.64K 10-K/A · filed 2021-06-16 | $3.64K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |